Found 1 Presentation For Request "572P"
572P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
- Javier Pozas (Madrid, Spain)
Abstract
Background
Endocrine neoplasms encompass a heterogeneous group of tumors, some of which lack optimal therapeutic options. The emergence of new targeted agents directed against specific genetic alterations may change their clinical outcome. We evaluated the prevalence of genetic alterations among advanced endocrine tumors and outcomes of patients treated with targeted agents.
Methods
Retrospective study of patients with advanced endocrine tumors evaluated with a DNA-based next generation sequencing (NGS) platform for a molecular and personalized therapeutic approach during 2020.
Results
The analysis of 27 endocrine tumors identified 76 pathogenic alterations and 175 variants of uncertain significance. Most mutations occurred in genes involved in tyrosine kinase pathways (50%), chromatin remodeling (17%), DNA damage repair (12%) and transcription regulation (12%). In 5 patients (pts) with neuroendocrine carcinomas, mutations in
Conclusions
70% of pts harbored an actionable mutation. Targeted therapy resulted in outstanding response rates and may have a significant survival benefit in aggressive tumors, such as ATC. Genetic alterations in targetable genes should be routinely evaluated in advanced endocrine tumors.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Molina-Cerrillo: Financial Interests, Personal, Invited Speaker: IPSEN; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: EISAI; Financial Interests, Personal, Research Grant: Pfizer; Financial Interests, Personal, Research Grant: IPSEN. P. Valderrábano: Financial Interests, Personal, Writing Engagements: Sanofi-Genzyme; Financial Interests, Personal, Invited Speaker: Esteve. A. Carrato Mena: Non-Financial Interests, Institutional, Advisory Role: Roche; Non-Financial Interests, Institutional, Advisory Role: Bayer; Non-Financial Interests, Institutional, Advisory Role: Merk; Non-Financial Interests, Institutional, Advisory Role: MSD; Non-Financial Interests, Institutional, Advisory Role: BMS; Non-Financial Interests, Institutional, Advisory Role: Servier; Non-Financial Interests, Institutional, Advisory Role: Celgene; Non-Financial Interests, Institutional, Advisory Role: Shire; Non-Financial Interests, Institutional, Advisory Role: Mylan. P. Garrido Lopez: Financial Interests, Personal, Advisory Board: Abbvie; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Gebro; Financial Interests, Personal, Advisory Board: GlaxoSmithKline; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: Nordic; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Principal Investigator: Apollomics; Financial Interests, Personal, Principal Investigator: Array Biopharma; Financial Interests, Personal, Principal Investigator: BluePrint; Financial Interests, Personal, Principal Investigator: IO Biotech; Non-Financial Interests, Personal, Leadership Role: AECC; Non-Financial Interests, Personal, Leadership Role: ESMO; Non-Financial Interests, Personal, Leadership Role: FACME; Non-Financial Interests, Personal, Leadership Role: IASLC; Non-Financial Interests, Personal, Leadership Role: SEOM. T. Alonso-Gordoa: Financial Interests, Personal, Invited Speaker: IPSEN; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal, Advisory Role: Janssen-Cilag; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: EISAI; Financial Interests, Personal, Invited Speaker: Merck. All other authors have declared no conflicts of interest.